Salisbury Foundation Trust

FOI_5880

Internal Reference Number: FOI_5880

Date Request Received: 09/10/2020 11:36:33

Date Request Replied To: 06/11/2020 11:06:34

This response was sent via: By Email

Request Summary: supply of ICU medicines

Request Category: Private Individuals







 
Question Number 1:
Confirm or deny whether disruption to supply of ICU medicines is included as a risk on the Trust's risk register
 
Answer To Question 1:
6360 - Medication supply concerns during COVID19
Description of Risk - A number of key ITU and EoL drugs are being reported nationally as in limited stock. The trust is now under restricted ordering for:-
- Propofol
- Noradrenaline
- Morphine injections
- Atracurium
This means we are generally able to access 1-2 weeks of stock based on our current usage but may struggle to source additional stock if the number of ITU and EoL beds increase.
 
Question Number 2:
Confirm or deny whether disruption to supply of noradrenaline is included as a risk on the Trust's risk register
 
Answer To Question 2:
6360 - Medication supply concerns during COVID19
Description of Risk - A number of key ITU and EoL drugs are being reported nationally as in limited stock. The trust is now under restricted ordering for:-
- Propofol
- Noradrenaline
- Morphine injections
- Atracurium

This means we are generally able to access 1-2 weeks of stock based on our current usage but may struggle to source additional stock if the number of ITU and EoL beds increase.


 
Question Number 3:
With regards to the above 2 questions:
a. When were the risks put on the register
b. When are they to be reviewed
c. What significance status have they been given. e.g. use of a RAG-rating system
 
Answer To Question 3:
a. When were the risks put on the register?
Risk 6360 – 10th April 2020

b. When are they to be reviewed?
Risk 6360 – closed 8th July 2020

c. What significance status have they been given? e.g. use of a RAG-rating system

Risk 6360
Initial L3 X C3 = 9 high
Current L2 X C3 = 6 Moderate
Target L2 X C2 = 4 Moderate
 
Question Number 4:
Provide the number of safety incidents recorded at your Trust which relate to the preparation and /or the manipulation/mixing of medicines in critical care areas between 1 January 2019 and 1 September 2020
 
Answer To Question 4:
see attached spread sheetCopy of FO1 question 4.xlsx
 
Question Number 5:
Provide the number of safety incidents recorded at your Trust which relate to administration, preparation, and/or the manipulation/mixing of noradrenaline at the bedside between 1 January 2019 and 1 September 2020. Provide details of the reported cases.
 
Answer To Question 5:
see attached spreadsheetCopy of FO1 question 5.xlsx
 
Question Number 6:
Confirm or deny if your Trust has taken action to adhere to the guidance published by the Royal Pharmaceutical Society, titled Safe and Secure Handling of Medicines (December 2018), specifically with regards to appendix C and, "as outlined in the core guidance, manipulation of medicines in clinical areas is minimised and medicines are presented as prefilled syringes or other 'ready-to-administer' preparations wherever possible..." https://www.rpharms.com/recognition/setting-professional-standards/safe-and-secure-handling-of-medicines/professional-guidance-on-the-safe-and-secure-handling-of-medicines
 
Answer To Question 6:
Yes
 
Question Number 7:
Confirm or deny if your Trust subscribes to and follows the guidance provided on IV administration of medication by the MEDUSA injectable medicines guide.
 
Answer To Question 7:
Yes
 
Question Number 8:
Supply evidence of the process the Trust has taken to address the principles outlined in the guidance above, specifically with regards to "the manipulation of medicines in clinical areas is minimised and medicines are presented as prefilled syringes or other 'ready-to-administer' preparations..."
 
Answer To Question 8:
Each individual high risk injectable product has a risk assessment completed as part of the formulary application.
 
Question Number 9:
Confirm or deny whether your Trust is stockpiling ready-to-use or ready-to-administer noradrenaline for the likely increased demand over the next 6 months (stockpiling is defined as retaining medicines with a shelf-life of at least 12 months)
 
Answer To Question 9:
No
Please see attachments:
Copy of FO1 question 4.xlsx
Copy of FO1 question 5.xlsx
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values